NCT01458171 - Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

April 30, 2012

Conditions

Primary Immune Deficiency Disorder

Interventions

BIOLOGICAL

Immune globulin subcutaneous (Human)

IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use. Subjects will receive weekly infusions of IgPro20 for a total of 24 weeks at a dose based on the subject's IgPro20 dose in the pivotal study ZLB06\_002CR (NCT01199705).

Trial Locations (9)

466-8560

Study site, Nagoya

260-8677

Study site, Chiba

812-8582

Study site, Fukuoka

502-8558

Study site, Gifu

060-8648

Study site, Sapporo

570-8507

Study site, Moriguchi

343-8555

Study site, Koshigaya

359-8513

Study site, Tokorozawa

113-8519

Study site, Bunkyō City